Treating Resistant Depression Market through Alternative Therapies
![]() |
Treating Resistant Depression Market |
The
treatment resistant depression market is gaining traction with increasing
popularity of alternative treatment methods like cannabidiol (CBD). Treatment
resistant depression refers to depression that does not improve after adequate
treatment with antidepressant medications. An estimated 30% to 40% of people
diagnosed with depression do not achieve remission even after trying multiple
standard treatments. The growing instances of resistant depression has boosted
the need for novel treatment approaches offering relief through non-addictive
means.
Products like CBD oils extracted from hemp plants have emerged as promising alternatives
for managing symptoms of depression. CBD is one of over 100 chemical compounds
known as cannabinoids found in the cannabis plant. It has neuroprotective and
anti-inflammatory properties but does not cause the intoxicating ‘high’ of
tetrahydrocannabinol (THC). Numerous studies have linked CBD to reduction in
anxiety, cognitive impairment and pain symptoms in a variety of illnesses
including depression. Its advantage lies in addressing the underlying causes of
depression rather than just focusing on symptoms. CBD oils are also not
associated with side-effects of pharmaceutical antidepressants like insomnia,
fatigue and nausea.
The Global
Treatment Resistant Depression Market Demand is estimated to be valued
at US$ 1405.58 Mn in 2024 and is expected to exhibit a CAGR of 22% over the
forecast period 2024 to 2030.
Key Takeaways
Key players operating in the treatment resistant depression market are
HempFlax, Cavac Biomateriaux, BaFa, Hemp Planet, Dunagro, American Hemp,
Hempline, Hemp Inc, Ecofibre, GenCanna, Hemp Oil Canada, Hemp Poland, Plains
Industrial Hemp Processing, Colorado Hemp Works, MH Medical Hemp, Hempco,
Hempfield Farms, Hemp Tech, Tilray, Canopy Growth.
The rising prevalence of depression globally coupled with limited efficacy of
available antidepressants is driving the demand for alternative treatments like
CBD. According to WHO, over 260 million people are affected by depression
worldwide. Nearly 50% of these patients do not respond adequately to first line
or second line drug therapies heightening the need for new treatment methods.
The untapped growth potential of emerging markets across Asia Pacific and Latin
America has prompted leading CBD suppliers to expand their geographical
footprint in these regions. Asia Pacific is expected witness the fastest CAGR
during the forecast period supported by growing acceptance of herbal
supplements in India and China. Promising clinical studies have raised hopes
that CBD could emerge as a mainstream depression treatment in view of its
safety, tolerability and multifaceted mechanism of action.
Market Key Trends
One of the major trends in the treatment resistant depression market is the
standardization of CBD formulations. Currently, substantial variability exists
in the quality, purity and concentration between CBD-based products due to
loose regulations. This undermines the credibility of research and discourages
medical acceptance. Treatment resistant depression is a serious condition
requiring carefully evaluated therapeutic solutions. Hence, market players are
collaborating with research institutes to develop standardized CBD dosing
protocols and manufacturing practices. This will strengthen clinical evidence,
empower healthcare providers and expand consumer access to clinically-effective
goods.
Porter's
Analysis
Threat of new entrants: Low barriers to entry due to established distribution
channels and consumer familiarity with depression treatment options.
Bargaining power of buyers: Buyers have moderate bargaining power due to
availability of substitutes and standard treatment options.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to
differentiated products and technical expertise required.
Threat of new substitutes: Threat of new substitutes is high due to ongoing
research in innovative treatment methods.
Competitive rivalry: Intense competition exists among existing players to
develop more effective drugs.
Geographical regions of concentration
North America currently dominates the market accounting for over 40% of global
market value due to high treatment costs and greater awareness. The United
States represents the single largest market globally.
Fastest growing geographical region
Asia Pacific region is expected to grow at the fastest rate during the forecast
period driven by rising prevalence of mental health issues, growing geriatric
population susceptible to depression and improved access to modern treatment
options in major countries like China and India.
For more details on the report, Read- https://www.rapidwebwire.com/treatment-resistant-depression-market-demand-share-analysis/
Comments
Post a Comment